ATE211392T1 - Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen - Google Patents

Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen

Info

Publication number
ATE211392T1
ATE211392T1 AT97906022T AT97906022T ATE211392T1 AT E211392 T1 ATE211392 T1 AT E211392T1 AT 97906022 T AT97906022 T AT 97906022T AT 97906022 T AT97906022 T AT 97906022T AT E211392 T1 ATE211392 T1 AT E211392T1
Authority
AT
Austria
Prior art keywords
gdnf
neurotrophic factor
vestibular
neurons
hearing disorders
Prior art date
Application number
AT97906022T
Other languages
English (en)
Inventor
Ella Magal
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/606,176 external-priority patent/US5837681A/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE211392T1 publication Critical patent/ATE211392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97906022T 1996-02-23 1997-02-14 Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen ATE211392T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/606,176 US5837681A (en) 1996-02-23 1996-02-23 Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US08/710,219 US5929041A (en) 1996-02-23 1996-09-13 Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
PCT/US1997/002677 WO1997030722A1 (en) 1996-02-23 1997-02-14 Use of glial neurotrophic factor (gdnf) for treatment of hearing disorders

Publications (1)

Publication Number Publication Date
ATE211392T1 true ATE211392T1 (de) 2002-01-15

Family

ID=27085161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906022T ATE211392T1 (de) 1996-02-23 1997-02-14 Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen

Country Status (21)

Country Link
US (1) US5929041A (de)
EP (1) EP0822829B1 (de)
JP (1) JP4028598B2 (de)
KR (1) KR100271247B1 (de)
CN (1) CN1130221C (de)
AT (1) ATE211392T1 (de)
AU (1) AU691443B2 (de)
CA (1) CA2217565C (de)
CZ (1) CZ322797A3 (de)
DE (1) DE69709458T2 (de)
DK (1) DK0822829T3 (de)
EA (1) EA199700225A1 (de)
ES (1) ES2170938T3 (de)
HU (1) HU223999B1 (de)
IL (1) IL121790A (de)
MX (1) MX9707669A (de)
NO (1) NO974767L (de)
NZ (1) NZ328918A (de)
PT (1) PT822829E (de)
SK (1) SK138697A3 (de)
WO (1) WO1997030722A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
SI1005358T1 (en) * 1997-07-30 2003-06-30 Amgen Inc. Use of a neurturin protein product for preventing and treating hearing loss
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US7236888B2 (en) * 1998-03-06 2007-06-26 The Regents Of The University Of California Method to measure the activation state of signaling pathways in cells
US6304787B1 (en) 1998-08-26 2001-10-16 Advanced Bionics Corporation Cochlear electrode array having current-focusing and tissue-treating features
US6309410B1 (en) 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
EP1126855B1 (de) 1998-09-25 2007-05-09 Cephalon, Inc. Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
AU781802B2 (en) * 1999-06-01 2005-06-16 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
EP1223966B1 (de) * 1999-10-29 2003-05-02 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Verwendung von gdnf für behandlung von hornhautdefekten
US6551575B1 (en) 1999-12-02 2003-04-22 Neurosciences Research Foundation, Inc. Methods for identifying compounds for motion sickness, vertigo and other disorders related to balance and the perception of gravity
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
AUPR148400A0 (en) * 2000-11-14 2000-12-07 Cochlear Limited Apparatus for delivery of pharmaceuticals to the cochlea
US9089450B2 (en) * 2000-11-14 2015-07-28 Cochlear Limited Implantatable component having an accessible lumen and a drug release capsule for introduction into same
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
AUPS081502A0 (en) * 2002-02-28 2002-03-21 Cochlear Limited Connector for drug delivery system
EP1547618B1 (de) * 2002-10-02 2010-05-26 AnGes MG, Inc. Arzneimittel gegen hörfunktionsstörungen
WO2004050056A1 (en) * 2002-11-29 2004-06-17 Cochlear Limited Cochlear implant drug delivery device
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US8133215B2 (en) * 2007-08-13 2012-03-13 Cochlear Limited Independently-manufactured drug delivery module and corresponding receptacle in an implantable medical device
US8271101B2 (en) * 2007-08-29 2012-09-18 Advanced Bionics Modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead
US8190271B2 (en) * 2007-08-29 2012-05-29 Advanced Bionics, Llc Minimizing trauma during and after insertion of a cochlear lead
EP2278999B1 (de) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8617097B2 (en) 2010-05-24 2013-12-31 Cochlear Limited Drug-delivery accessory for an implantable medical device
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
JP2017508793A (ja) * 2014-03-05 2017-03-30 シュワルツ、ローレンス エム.SCHWARTZ, Lawrence M. 感覚細胞を保護するための方法及び組成物
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
JP2019517787A (ja) * 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
JP2019535267A (ja) 2016-11-10 2019-12-12 ケロス セラピューティクス インコーポレイテッドＫｅｒｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｇｄｎｆ融合ポリペプチド及びその使用方法
EP3406259A1 (de) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophine zur verwendung bei der behandlung von hörverlust
SI3737233T1 (sl) * 2018-01-09 2025-10-30 Dompé Farmaceutici S.P.A. Ušesne formulacije z rastnimi faktorji
CN112920998B (zh) * 2021-02-05 2022-06-14 复旦大学附属眼耳鼻喉科医院 一种成年鼠耳蜗体培养体系的建立方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
MX9205293A (es) * 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
JP4098355B2 (ja) * 1993-08-12 2008-06-11 ニューロテック ユーエスエー， インコーポレイテッド 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
DE69709458T2 (de) 2002-08-29
CN1181704A (zh) 1998-05-13
CA2217565A1 (en) 1997-08-28
US5929041A (en) 1999-07-27
PT822829E (pt) 2002-06-28
CA2217565C (en) 2002-04-16
NO974767L (no) 1997-12-22
SK138697A3 (en) 1998-02-04
AU691443B2 (en) 1998-05-14
CZ322797A3 (cs) 1998-01-14
MX9707669A (es) 1997-11-29
AU2277997A (en) 1997-09-10
NZ328918A (en) 1999-08-30
CN1130221C (zh) 2003-12-10
KR100271247B1 (ko) 2000-11-01
IL121790A0 (en) 1998-02-22
HUP9901758A3 (en) 2001-10-29
WO1997030722A1 (en) 1997-08-28
ES2170938T3 (es) 2002-08-16
NO974767D0 (no) 1997-10-15
HUP9901758A2 (hu) 1999-08-30
EP0822829B1 (de) 2002-01-02
EA199700225A1 (ru) 1998-04-30
KR19980703748A (ko) 1998-12-05
DK0822829T3 (da) 2002-04-02
EP0822829A1 (de) 1998-02-11
IL121790A (en) 2002-08-14
JPH11504351A (ja) 1999-04-20
HU223999B1 (hu) 2005-04-28
JP4028598B2 (ja) 2007-12-26
DE69709458D1 (de) 2002-02-07

Similar Documents

Publication Publication Date Title
ATE211392T1 (de) Verwendung des glialen, neurotrophen faktors (gdnf) zur behandlung von gehörstörungen
ATE230607T1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
DK0866719T3 (da) Fremgangsmåde til behandling af retina-gangliecellelæsion under anvendelse af gliacellelinjeafladt neurotrof faktor (GDNF)-
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ES2074276T3 (es) Metodo de tratamiento de la alopecia.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69527052D1 (de) Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten
DE60026568D1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE316529T1 (de) Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns)
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
EP1304119A3 (de) Verfahren zur Vorbeugung und Behandlung von Gehörverlust mit Neurturin Protein
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
DE69516602D1 (de) Verwendung von Bifemelan zur Herstellung eines Arzneimittels zur Behandlung der Hyperkinesie
WO2001072955A3 (en) Regulation of human nedd1-related protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification